Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis

Tsutomu Takeuchi, Shinichi Kawai, Kazuhiko Yamamoto, Masayoshi Harigai, Kota Ishida, Nobuyuki Miyasaka

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives A post-marketing surveillance (PMS) program was implemented to assess the safety and effectiveness of tacrolimus (TAC) in Japanese rheumatoid arthritis (RA) patients and to identify risk factors related to adverse drug reactions (ADRs). Methods Patients were registered centrally and monitored for all adverse events (AEs) for 24 weeks. Effectiveness was evaluated using the Disease Activity Score 28-CRP (DAS28-CRP). Results Data from 3,172 patients (mean age 62.2 years) were evaluated in the safety analysis. Of the safety population, 78.5 %were female and 25.9 % were in Steinbrocker's functional class 3 or 4. TAC was prescribed as monotherapy in 52.5 % and the most common concomitant disease modifying antirheumatic drug (DMARD) was methotrexate, used in 28.9 % of the patients. The incidence of AEs, serious AEs (SAEs), ADRs and serious ADRs were 41.2, 6.4, 36.0, and 4.9 %, respectively. The most frequent serious ADR category was infections and infestations. Age ≥ 65 years, concurrent renal dysfunction, and concurrent diabetes mellitus were identified as significant risk factors for ADR. Based on EULAR response criteria, 65.4 % of the patients showed moderate or good response. Conclusions The results demonstrate that TAC is well tolerated by Japanese patients with active RA, including those receiving concomitant methotrexate, in the real world.

Original languageEnglish
Pages (from-to)8-16
Number of pages9
JournalModern Rheumatology
Volume24
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Tacrolimus
Marketing
Drug-Related Side Effects and Adverse Reactions
Rheumatoid Arthritis
Safety
Methotrexate
Antirheumatic Agents
Diabetes Mellitus
Kidney
Incidence
Infection
Population

Keywords

  • Effectiveness
  • Post-marketing surveillance
  • Rheumatoid arthritis
  • Safety
  • Tacrolimus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. / Takeuchi, Tsutomu; Kawai, Shinichi; Yamamoto, Kazuhiko; Harigai, Masayoshi; Ishida, Kota; Miyasaka, Nobuyuki.

In: Modern Rheumatology, Vol. 24, No. 1, 2014, p. 8-16.

Research output: Contribution to journalArticle

Takeuchi, Tsutomu ; Kawai, Shinichi ; Yamamoto, Kazuhiko ; Harigai, Masayoshi ; Ishida, Kota ; Miyasaka, Nobuyuki. / Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. In: Modern Rheumatology. 2014 ; Vol. 24, No. 1. pp. 8-16.
@article{f81b617744234590b0673e354913b8cb,
title = "Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis",
abstract = "Objectives A post-marketing surveillance (PMS) program was implemented to assess the safety and effectiveness of tacrolimus (TAC) in Japanese rheumatoid arthritis (RA) patients and to identify risk factors related to adverse drug reactions (ADRs). Methods Patients were registered centrally and monitored for all adverse events (AEs) for 24 weeks. Effectiveness was evaluated using the Disease Activity Score 28-CRP (DAS28-CRP). Results Data from 3,172 patients (mean age 62.2 years) were evaluated in the safety analysis. Of the safety population, 78.5 {\%}were female and 25.9 {\%} were in Steinbrocker's functional class 3 or 4. TAC was prescribed as monotherapy in 52.5 {\%} and the most common concomitant disease modifying antirheumatic drug (DMARD) was methotrexate, used in 28.9 {\%} of the patients. The incidence of AEs, serious AEs (SAEs), ADRs and serious ADRs were 41.2, 6.4, 36.0, and 4.9 {\%}, respectively. The most frequent serious ADR category was infections and infestations. Age ≥ 65 years, concurrent renal dysfunction, and concurrent diabetes mellitus were identified as significant risk factors for ADR. Based on EULAR response criteria, 65.4 {\%} of the patients showed moderate or good response. Conclusions The results demonstrate that TAC is well tolerated by Japanese patients with active RA, including those receiving concomitant methotrexate, in the real world.",
keywords = "Effectiveness, Post-marketing surveillance, Rheumatoid arthritis, Safety, Tacrolimus",
author = "Tsutomu Takeuchi and Shinichi Kawai and Kazuhiko Yamamoto and Masayoshi Harigai and Kota Ishida and Nobuyuki Miyasaka",
year = "2014",
doi = "10.3109/14397595.2013.854074",
language = "English",
volume = "24",
pages = "8--16",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis

AU - Takeuchi, Tsutomu

AU - Kawai, Shinichi

AU - Yamamoto, Kazuhiko

AU - Harigai, Masayoshi

AU - Ishida, Kota

AU - Miyasaka, Nobuyuki

PY - 2014

Y1 - 2014

N2 - Objectives A post-marketing surveillance (PMS) program was implemented to assess the safety and effectiveness of tacrolimus (TAC) in Japanese rheumatoid arthritis (RA) patients and to identify risk factors related to adverse drug reactions (ADRs). Methods Patients were registered centrally and monitored for all adverse events (AEs) for 24 weeks. Effectiveness was evaluated using the Disease Activity Score 28-CRP (DAS28-CRP). Results Data from 3,172 patients (mean age 62.2 years) were evaluated in the safety analysis. Of the safety population, 78.5 %were female and 25.9 % were in Steinbrocker's functional class 3 or 4. TAC was prescribed as monotherapy in 52.5 % and the most common concomitant disease modifying antirheumatic drug (DMARD) was methotrexate, used in 28.9 % of the patients. The incidence of AEs, serious AEs (SAEs), ADRs and serious ADRs were 41.2, 6.4, 36.0, and 4.9 %, respectively. The most frequent serious ADR category was infections and infestations. Age ≥ 65 years, concurrent renal dysfunction, and concurrent diabetes mellitus were identified as significant risk factors for ADR. Based on EULAR response criteria, 65.4 % of the patients showed moderate or good response. Conclusions The results demonstrate that TAC is well tolerated by Japanese patients with active RA, including those receiving concomitant methotrexate, in the real world.

AB - Objectives A post-marketing surveillance (PMS) program was implemented to assess the safety and effectiveness of tacrolimus (TAC) in Japanese rheumatoid arthritis (RA) patients and to identify risk factors related to adverse drug reactions (ADRs). Methods Patients were registered centrally and monitored for all adverse events (AEs) for 24 weeks. Effectiveness was evaluated using the Disease Activity Score 28-CRP (DAS28-CRP). Results Data from 3,172 patients (mean age 62.2 years) were evaluated in the safety analysis. Of the safety population, 78.5 %were female and 25.9 % were in Steinbrocker's functional class 3 or 4. TAC was prescribed as monotherapy in 52.5 % and the most common concomitant disease modifying antirheumatic drug (DMARD) was methotrexate, used in 28.9 % of the patients. The incidence of AEs, serious AEs (SAEs), ADRs and serious ADRs were 41.2, 6.4, 36.0, and 4.9 %, respectively. The most frequent serious ADR category was infections and infestations. Age ≥ 65 years, concurrent renal dysfunction, and concurrent diabetes mellitus were identified as significant risk factors for ADR. Based on EULAR response criteria, 65.4 % of the patients showed moderate or good response. Conclusions The results demonstrate that TAC is well tolerated by Japanese patients with active RA, including those receiving concomitant methotrexate, in the real world.

KW - Effectiveness

KW - Post-marketing surveillance

KW - Rheumatoid arthritis

KW - Safety

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=84896867064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896867064&partnerID=8YFLogxK

U2 - 10.3109/14397595.2013.854074

DO - 10.3109/14397595.2013.854074

M3 - Article

VL - 24

SP - 8

EP - 16

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 1

ER -